Pfizer, Medivation's phase 3 study for Huntington's disease drug fails Print E-mail
By Deborah Sterescu - Proactiveinvestors.com   
Monday, 11 April 2011 14:20

Pfizer (NYSE:PFE) and Medivation (NASDAQ:MDVN) announced Monday disappointing results from their phase 3 trial for dimebon, a drug designed to treat patients with Huntington's disease, a disorder in which nerve cells in the brain degenerate.


The drug, known as latrepirdine in its generic form, did not achieve statistical significance  for either of the two main goals of the Horizon study, which measured cognition and global function, the companies said.

"We are disappointed with the results of the HORIZON trial given the high unmet need in this patient population," said president and CEO of Medivation, David Hung.

"At this point, we will discontinue development of dimebon in Huntington disease, including the ongoing open-label extension study."

Medivation and Pfizer did say, however, that they will continue an ongoing 12-month phase 3 study for the drug in patients with mild to moderate Alzheimer's disease, for which results are expected in the first half of 2012.

The phase 3 Horizon trial enrolled 403 patients with Huntington disease at 64 sites in North America, Europe and Australia. Patients were randomized to receive either 20 mg of dimebon three times daily, or placebo, for six months.

The study was conducted under a global collaboration agreement between Pfizer and Medivation to develop and commercialize dimebon for the treatment of Alzheimer's disease and Huntington's disease.

“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here http://www.proactiveinvestors.com/pages/terms




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter